Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


There’s a vaccine that can prevent disease caused by Haemophilus influenzae type b (Hib), but not the other types ("strains") of Haemophilus influenzae bacteria.

Vaccine for Hib Only

The first Haemophilus influenzae type b (Hib) vaccine was licensed in 1985. Scientists later reformulated the vaccine so that it would be effective in young children, and the Food and Drug Administration (FDA) licensed this improved version in 1987 (for children) and 1990 (for infants). The currently used Hib vaccine protects infants as young as six weeks old. This vaccine also protects adolescents and adults who are at increased risk for Hib disease.

Before the introduction of Hib vaccine, Hib was the leading cause of bacterial meningitis among children younger than five years of age in the United States. Every year about 20,000 children younger than five years of age got severe Hib disease and about 1,000 children died. More than half of the children who developed severe Hib disease were younger than one year of age. Due to the use of Hib vaccine, by 2012, less than 50 cases of Hib disease occurred annually in children younger than age five years.

What You Need to Know about the Hib Vaccine

Hib Vaccine Resources for Health Care Professionals

Vaccination Coverage

The National Immunization Survey (NIS) is a large, on-going survey of immunization coverage among US pre-school children (19 - 35 months of age). In conjunction with the NIS, CDC also conducts the NIS-Teen (13 to 17 years of age) and the NIS-Adult.

 Top of Page